Ginkgo Bioworks (NYSE: DNA – Get a rating) saw its price target lowered by research analysts BTIG Research to $5.00 in a report on Wednesday, Target Stock Advisor reports. The company currently has a “na” rating on the stock. BTIG Research’s target price suggests a potential upside of 102.43% from the company’s previous close.
A number of other stock analysts also weighed in on DNA. Bank of America downgraded shares of Ginkgo Bioworks from a “neutral” rating to an “underperforming” rating and set a price target of $3.00 for the company. in a research report Wednesday. Zacks Investment Research downgraded shares of Ginkgo Bioworks from a “buy” rating to a “hold” rating in a Monday, April 4 research report. Cowen launched coverage on Ginkgo Bioworks shares in a research report on Wednesday, March 2. They set an “outperform” rating and a price target of $12.00 for the company. Raymond James set a price target of $11.50 on Ginkgo Bioworks shares and gave the stock an “outperform” rating in a research report on Tuesday. Finally, the Goldman Sachs group launched a hedge on the shares of Ginkgo Bioworks in a research report on Wednesday, February 23. They set a “neutral” rating and a price target of $7.00 for the company. One analyst rated the stock with a sell rating, two gave the company a hold rating and five gave the company’s stock a buy rating. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $8.25.
NYSE DNA shares were down $0.27 on Wednesday, hitting $2.47. The company’s stock had a trading volume of 1,147,733 shares, compared to an average volume of 21,294,068. Ginkgo Bioworks has a 12-month low of $2.09 and a 12-month high of $15.86. The company has a quick ratio of 12.76, a current ratio of 12.79 and a leverage ratio of 0.01. The stock has a 50-day moving average of $3.32 and a 200-day moving average of $6.62.
Ginkgo Bioworks (NYSE: DNA – Get a rating) last released its quarterly earnings data on Monday, May 16. The company reported ($0.30) earnings per share for the quarter, missing analyst consensus estimates of ($0.04) by ($0.26). Equity analysts expect Ginkgo Bioworks to post -0.13 EPS for the current fiscal year.
Several hedge funds have recently changed their positions in the company. Evergreen Capital Management LLC bought a new position in Ginkgo Bioworks stock in the first quarter worth $173,000. Captrust Financial Advisors increased its equity stake in Ginkgo Bioworks by 226.7% in the first quarter. Captrust Financial Advisors now owns 16,333 shares of the company worth $66,000 after purchasing an additional 11,333 shares during the period. State Street Corp increased its equity stake in Ginkgo Bioworks by 5.3% in the first quarter. State Street Corp now owns 4,000,068 shares of the company worth $16,120,000 after purchasing an additional 202,403 shares during the period. Autonomy Capital Jersey LP acquired a new stake in shares of Ginkgo Bioworks during the first quarter at a value of $557,000. Finally, Plustick Management LLC acquired a new stake in the shares of Ginkgo Bioworks in Q1 for a value of approximately $6,247,000. Institutional investors and hedge funds hold 46.93% of the company’s shares.
Ginkgo Bioworks Company Profile (Get a rating)
Ginkgo Bioworks Holdings, Inc., in collaboration with its subsidiaries, is developing a cell programming platform. Its platform is used to program cells to enable the biological production of products, such as novel therapeutics, food ingredients, and petroleum-derived chemicals. The company serves a variety of end markets, including specialty chemicals, agriculture, food, consumer products and pharmaceuticals.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Ginkgo Bioworks right now?
Before you consider Ginkgo Bioworks, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Ginkgo Bioworks was not on the list.
While Ginkgo Bioworks currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here